Pay in 4 interest-free payments of $6.76 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Methods This retrospective, database study used Optums de-identified Clinformatics Data Mart Database to identify glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment-nave adult patients with type 2 diabetes (T2D) initiating semaglutide QW, dulaglutide, liraglutide, or exenatide QW between January 1, 2018 and April 30, 2019
Patients should continue to report any new side effects, changes in medication or significant health changes during treatment so their prescriber can review whether treatment remains appropriate
Have a question or concern
Semaglutide GLP-1 is formulated to provide long-lasting appetite control because it is typically administered once per week
At 2.5mg/ml, a 0.25mg dose requires drawing just 0.1ml (10 units on an insulin syringe)
